Joseph P. Eder

24.5k total citations · 5 hit papers
178 papers, 12.2k citations indexed

About

Joseph P. Eder is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Joseph P. Eder has authored 178 papers receiving a total of 12.2k indexed citations (citations by other indexed papers that have themselves been cited), including 128 papers in Oncology, 66 papers in Molecular Biology and 53 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Joseph P. Eder's work include Cancer Immunotherapy and Biomarkers (47 papers), Cancer therapeutics and mechanisms (31 papers) and Lung Cancer Treatments and Mutations (29 papers). Joseph P. Eder is often cited by papers focused on Cancer Immunotherapy and Biomarkers (47 papers), Cancer therapeutics and mechanisms (31 papers) and Lung Cancer Treatments and Mutations (29 papers). Joseph P. Eder collaborates with scholars based in United States, South Korea and Spain. Joseph P. Eder's co-authors include Barbara Burtness, Patricia LoRusso, Jared Lunceford, Cristina Cruz, Fadi S. Braiteh, Jonathan D. Cheng, Daniel S. Chen, Howard A. Burris, Laura Q.M. Chow and Tanguy Y. Seiwert and has published in prestigious journals such as Nature, New England Journal of Medicine and Journal of Biological Chemistry.

In The Last Decade

Joseph P. Eder

174 papers receiving 12.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

2014 1.9k citations Joseph P. Eder, Fadi S. Braiteh et al. profile →
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

2016 1.3k citations Tanguy Y. Seiwert, Barbara Burtness et al. The Lancet Oncology profile →
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial

2016 848 citations Kei Muro, Shilpa Gupta et al. The Lancet Oncology profile →
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer

2018 567 citations Leisha A. Emens, Cristina Cruz et al. profile →
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012

2018 329 citations Ranee Mehra, Tanguy Y. Seiwert et al. profile →

Peers

Countries citing papers authored by Joseph P. Eder

Since Specialization

Citations

This map shows the geographic impact of Joseph P. Eder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph P. Eder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph P. Eder more than expected).

Fields of papers citing papers by Joseph P. Eder

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joseph P. Eder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph P. Eder. The network helps show where Joseph P. Eder may publish in the future.

Co-authorship network of co-authors of Joseph P. Eder

This figure shows the co-authorship network connecting the top 25 collaborators of Joseph P. Eder. A scholar is included among the top collaborators of Joseph P. Eder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joseph P. Eder. Joseph P. Eder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Circulating Tumor DNA Dynamics Fail to Predict Efficacy of Poly(ADP-ribose) Polymerase/VEGFR Inhibition in Patients With Heavily Pretreated Advanced Solid Tumors 2024 ·JCO Precision Oncology ·(unknown), Azeet Narayan, (unknown), J. M. Wolfe, Dennis Vu, (unknown), (unknown), S. Percy Ivy, Joseph P. Eder, Yanhong Deng, Patricia LoRusso, Joseph W. Kim, Abhijit A. Patel	0
2	1079TiP A phase I first-in-human study of PRTH-101, an IgG1 monoclonal antibody targeting DDR1, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies 2023 ·Annals of Oncology ·Shiraj Sen, Alexander I. Spira, David Sommerhalder, Funda Meric‐Bernstam, Vivek Subbiah, Jordan Berlin, Apurvasena Parikh, Michael Cecchini, Rachel E. Sanborn, (unknown), (unknown), (unknown), (unknown), Guy T. Clifton, Joseph P. Eder, A. W. Tolcher	2
3	NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors 2023 ·Cancer Research Communications ·Michael Cecchini, Zenta Walther, Wei Wei, Navid Hafez, Mary Jo Pilat, Scott A. Boerner, Diane E. Durecki, Joseph P. Eder, Kurt A. Schalper, Alice P. Chen, Patricia LoRusso	2
4	Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma 2022 ·Journal for ImmunoTherapy of Cancer ·Robert I. Haddad, Tanguy Y. Seiwert, Laura Q.M. Chow, Shilpa Gupta, Jared Weiss, Iris Gluck, Joseph P. Eder, Barbara Burtness, Makoto Tahara, Bhumsuk Keam, Hyunseok Kang, Kei Muro, Andrew Albright, Robin Mogg, Mark Ayers, Lingkang Huang, Jared Lunceford, Răzvan Cristescu, Jonathan D. Cheng, Ranee Mehra	54
5	Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations) 2021 ·JCO Precision Oncology ·Haider Mahdi, Navid Hafez, Deborah B. Doroshow, Davendra Sohal, (unknown), T. Khanh, Patricia LoRusso, Juliane M. Jürgensmeier, (unknown), Jeffrey Sklar, Colin P. Glover, Brunella Felicetti, Emma Dean, Peter G. Mortimer, Geoffrey I. Shapiro, Joseph P. Eder	56
6	A Phase I Study of DLYE5953A, an Anti-LY6E Antibody Covalently Linked to Monomethyl Auristatin E, in Patients with Refractory Solid Tumors 2020 ·Clinical Cancer Research ·Sara M. Tolaney, T. Khanh, Joseph P. Eder, Patricia LoRusso, Colin D. Weekes, Sarat Chandarlapaty, Ching‐Wei Chang, (unknown), (unknown), (unknown), Flávia Brunstein, Montserrat Carrasco‐Triguero, Walter C. Darbonne, Jennifer M. Giltnane, W. Michael Flanagan, S. Renee Commerford, Alexander Ungewickell, Geoffrey I. Shapiro, Shanu Modi	15
7	First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1 2019 ·Clinical Cancer Research ·Neeta Somaiah, Matthew S. Block, Joseph W. Kim, Geoffrey I. Shapiro, T. Khanh, Patrick Hwu, Joseph P. Eder, Robin L. Jones, Hailing Lu, Jan H. ter Meulen, Chet Bohac, Michael Chen, Frank J. Hsu, Sacha Gnjatic, Seth M. Pollack	71
8	Abstract 2986: Atezolizumab in metastatic TNBC (mTNBC): Long-term clinical outcomes and biomarker analyses 2017 ·Cancer Research ·Peter Schmid, Cristina Cruz, Fadi S. Braiteh, Joseph P. Eder, Sara M. Tolaney, Irene Kuter, Rita Nanda, Cathie T. Chung, Philippe A. Cassier, Jean‐Pierre Delord, Michael S. Gordon, Yijin Li, Bo Liu, Carol O’Hear, Marcella Fassò, Luciana Molinero, Leisha A. Emens	92
9	Phase I studies of the novel carcinoembryonic antigen T-cell bispecific (CEA-CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients (pts) with metastatic colorectal cancer (mCRC) 2017 ·Annals of Oncology ·Neil H. Segal, (unknown), Ignacio Melero, Willeke Ros, (unknown), Aurélien Marabelle, (unknown), Joan Albanell, Emiliano Calvo, Víctor Moreno, James M. Cleary, Joseph P. Eder, Vaios Karanikas, (unknown), Federico Sandoval, (unknown), Sasha Sreckovic, Herbert I. Hurwitz, L. Paz-Ares, Josep Tabernero	23
10	A phase I study evaluating DLYE5953A, an antibody-drug conjugate targeting the tumor-associated antigen lymphocyte antigen 6 complex locus E (Ly6E), in patients (Pts) with solid tumors 2016 ·Annals of Oncology ·Shanu Modi, Joseph P. Eder, Patricia LoRusso, Colin D. Weekes, Sarat Chandarlapaty, Sara M. Tolaney, (unknown), D. Ross Camidge, (unknown), (unknown), (unknown), (unknown), Flávia Brunstein, Walter C. Darbonne, W. Michael Flanagan, Alexander Ungewickell, Geoffrey I. Shapiro	0
11	A Phase 1 first-in-human study of MEDI0680, an anti-PD-1 monoclonal antibody (mAb) in adult patients (pts) with advanced tumors 2016 ·Annals of Oncology ·Aung Naing, Sanjay Goel, Brendan D. Curti, Amy Weise, Joseph P. Eder, (unknown), Chris Morehouse, (unknown), Joyson Karakunnel, Jon Infante	1
12	Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial breakdown → 2016 ·The Lancet Oncology ·Tanguy Y. Seiwert, Barbara Burtness, Ranee Mehra, Jared Weiss, Raanan Berger, Joseph P. Eder, Karl Heath, Terrill K. McClanahan, Jared Lunceford, Christine K. Gause, Jonathan D. Cheng, Laura Q.M. Chow	1275
13	Phase 1/2 study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032 2015 ·Annals of Oncology ·Scott Antonia, Johanna C. Bendell, Matthew H. Taylor, Emiliano Calvo, Dirk Jäger, Filippo de Braud, Patrick A. Ott, M. Catherine Pietanza, Leora Horn, Dung T. Le, Michael A. Morse, José A. López-Martín, Paolo A. Ascierto, O. Christensen, Joseph F. Grosso, Jason S. Simon, Chensheng Lin, Joseph P. Eder	5
14	A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas 2012 ·Clinical Cancer Research ·David S. Hong, Razelle Kurzrock, Jeffrey G. Supko, Xiaoying He, Aung Naing, Jennifer J. Wheler, Donald P. Lawrence, Joseph P. Eder, Colin J. Meyer, Deborah A. Ferguson, James W. Mier, Marina Konopleva, Sergej Konoplev, Michael Andreeff, Donald Küfe, Hillard Lazarus, Geoffrey I. Shapiro, Bruce J. Dezube	197
15	Phase I Study of the c-raf-1 Antisense Oligonucleotide ISIS 5132 in Combination with Carboplatin and Paclitaxel in Patients with Previously Untreated, Advanced Non-small Cell Lung Cancer 2009 ·Journal of Thoracic Oncology ·Panos Fidias, Nathan A. Pennell, Anthony Boral, Geoffrey I. Shapiro, Arthur T. Skarin, Joseph P. Eder, T. Jesse Kwoh, Richard S. Geary, Bruce E. Johnson, Thomas J. Lynch, Jeffrey G. Supko	17
16	Phase I trial with a novel orally administered synthetic triterpenoid RTA 402 (CDDO-Me) in patients with solid tumors and lymphoid malignancies 2007 ·Molecular Cancer Therapeutics ·David S. Hong, Razelle Kurzrock, Jeffrey G. Supko, Donald P. Lawrence, Jennifer Wheeler, Joseph P. Eder, (unknown), James W. Mier, Marina Konopleva, Sergej Konoplev, Sühendan Ekmekçioglu, Michael Andreeff, (unknown), Donald Küfe, Colin J. Meyer, Geoffrey I. Shapiro, Bruce J. Dezube	4
17	Trials of 9‐Amino‐20(S)‐Camptothecin in Boston 1996 ·Annals of the New York Academy of Sciences ·Joseph P. Eder, Eric H. Rubin, Richard M. Stone, (unknown), (unknown), Jeffrey G. Supko, Nancy M. Kinchla, Thomas Lynch, Selwyn J. Hurwitz, (unknown), (unknown), Deborah Toppmeyer, Michael L. Grossbard, (unknown), Mark S. Huberman, (unknown), Lawrence N. Shulman, Donald Küfe	9
18	A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. 1992 ·Journal of Clinical Oncology ·Karen H. Antman, Lois Ayash, Anthony Elias, Catherine Wheeler, M Hunt, Joseph P. Eder, Beverly A. Teicher, J.D. Critchlow, (unknown), Lowell E. Schnipper	313
19	Hepatic venoocclusive disease in autologous bone marrow transplantation of solid tumors and lymphomas. 1990 ·Journal of Clinical Oncology ·Lois Ayash, M Hunt, Karen H. Antman, Lee M. Nadler, Catherine Wheeler, Tak Takvorian, Anthony Elias, Joseph H. Antin, (unknown), Joseph P. Eder	49
20	Cyclophosphamide and Thiotepa With Autologous Bone Marrow Transplantation in Patients With Solid Tumors 1988 ·JNCI Journal of the National Cancer Institute ·Joseph P. Eder, Karen H. Antman, Anthony Elias, Thomas C. Shea, Beverly A. Teicher, W. David Henner, S Schryber, Sylvia A. Holden, Robert W. Finberg, (unknown), Mary Flaherty, Rosemarie Mick, Lowell E. Schnipper, Emil Frei	42

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact